Moderna, Inc. - MRNA STOCK NEWS

Moderna (Nasdaq: MRNA) announced that Takeda Pharmaceutical (NYSE: TAK) submitted a New Drug Application (NDA) to the Japanese government for importing and distributing Moderna's COVID-19 vaccine candidate (mRNA-1273 or TAK-919). This NDA marks a significant step in the vaccine's clinical development in Japan. The Phase 1/2 study, involving 200 participants, is assessing the vaccine's safety and immunogenicity. Pending licensure, Takeda is set to distribute 50 million doses starting in the first half of 2021.

On March 4, 2021, Moderna and IBM announced plans to collaborate on technologies to enhance COVID-19 vaccine management. Their pilot program aims to improve supply chain visibility and real-time tracking of vaccine distribution, utilizing artificial intelligence, blockchain, and hybrid cloud technologies.

The initiative includes vaccine management solutions for secure data sharing between governments and healthcare providers, as well as a Digital Health Pass that allows individuals control over their health information, facilitating verification of vaccination status.

Moderna (MRNA) reported remarkable financial results for Q4 and FY 2020, achieving total revenue of $571 million for Q4 and $803 million for the full year, driven by COVID-19 vaccine sales and grants, a significant increase from $14 million and $60 million in 2019, respectively. As of December 31, 2020, cash reserves surged to $5.25 billion, up from $1.26 billion a year prior. Notably, the company increased its 2021 global manufacturing goal for its COVID-19 vaccine from 600 million to 700 million doses, with plans for 1.4 billion doses by 2022. Moderna's pipeline now includes 24 mRNA development programs, with 13 in clinical studies.

Moderna (MRNA) announced new capital investments to enhance its manufacturing capacity for the COVID-19 vaccine, targeting a global output of approximately 1.4 billion doses in 2022, assuming a 100 μg dosage. The flexibility to produce vaccine boosters for emerging variants is also a focus. The company has already increased its 2021 production plan from 600 million to 700 million doses, with ongoing efforts to optimize operations for up to 1 billion doses this fiscal year. Approximately 60 million doses have been shipped globally, with expectations to fulfill government contracts in 2021.

Moderna (MRNA) has successfully manufactured clinical trial material for its variant-specific vaccine, mRNA-1273.351, targeting the SARS-CoV-2 B.1.351 variant. The doses have been shipped to the NIH for a Phase 1 clinical trial, which will assess the vaccine's ability to boost immunity against variants. Moderna is also exploring various booster strategies, including a multivalent booster candidate and additional doses of its existing vaccine. Initial data suggests its current vaccine provides neutralizing activity against variants, but further measures are necessary to enhance immunity.

Moderna (Nasdaq: MRNA) announced its participation in three upcoming virtual investor conferences. The events include the SVB Leerink 10th Annual Global Healthcare Conference on February 25, 2021, at 1:00 p.m. ET, the Cowen & Co. 41st Annual Health Care Conference on March 1, 2021, at 8:00 a.m. ET, and the Barclays Global Healthcare Conference on March 11, 2021, at 10:20 a.m. ET. Live webcasts will be available on Moderna's investor website and archived for 30 days post-event. Moderna has significantly advanced in mRNA technology, delivering vaccines and therapeutics for various diseases, including COVID-19.

Moderna, Inc. (Nasdaq: MRNA) has supplied 45.4 million doses of its COVID-19 Vaccine to the U.S. Government, with an additional 33.2 million doses in the final production stages. Approximately 25.5 million doses have been administered. Recent short-term delays in production are not expected to impact monthly delivery targets. The company anticipates meeting commitments for all ordered doses, expediting the delivery of the first 300 million doses across various timeframes. Production ramp-up continues, with expected monthly releases of 30-35 million doses for February and March, increasing to 40-50 million by July.

Moderna (Nasdaq: MRNA) has announced a new order commitment from the Canadian Government for an additional 4 million doses of its COVID-19 vaccine, bringing the total to 44 million doses. This increase highlights the Canadian Government's efforts to ensure vaccine availability for its citizens. Moderna's CEO, Stephane Bancel, expressed appreciation for this collaboration and emphasized the confidence in the vaccine's efficacy. Health Canada previously authorized the vaccine for individuals aged 18 and older, demonstrating continued regulatory support for Moderna's mRNA technology.

Moderna (Nasdaq: MRNA) announced the U.S. government's purchase of 100 million additional doses of its COVID-19 vaccine, totaling 300 million confirmed orders. With 41 million doses supplied to date, over 22 million Americans have received the vaccine. Moderna aims to deliver the first 100 million doses by Q1 2021 and the second by Q2 2021, leveraging its U.S. manufacturing capabilities. The company has secured agreements for over 631.5 million doses with various countries, reinforcing its role in the global fight against COVID-19.